WHO Pharmaceuticals Newsletter
(No. 2, 2008)
In this issue we bring you the recommendations from the fifth meeting of the Advisory Committee on Safety of Medicinal Products (ACSoMP). Some of the recommendations relate to ongoing projects, such as the patient safety pilot project for expanding the scope of national pharmacovigilance centres; others refer to new initiatives, such as developing indicators for measuring pharmacovigilance capacity and the impact of interventions in countries. Worldwide serious, acute allergic-type reactions have been reported in patients who received contaminated heparin. We have included a brief summary of regulatory actions that followed these events.